From newly approved 4-drug frontline regimens to the expanding role of CAR T-cell therapy and bispecific antibodies, this Spring 2026 edition of Myeloma Today breaks down the clinical advances redefining what’s possible for myeloma patients today. You’ll also discover how a global movement reached over 60 million people during Myeloma Action Month — and why that momentum matters. 

Download a Copy (https://issuu.com/international-myeloma-foundation/docs/myeloma-today-spring-2026?fr=sNzE3NjkxNDEzMTc)   |    Subscribe to Myeloma Today (https://secure.myeloma.org/page/38012/subscriptions/1)